List of Excipients in Branded Drug DELSYM (DEXTROMETHORPHAN)

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Atlantic Biologicals Corps	DELSYM (DEXTROMETHORPHAN)	dextromethorphan	17856-0276	CITRIC ACID MONOHYDRATE
Atlantic Biologicals Corps	DELSYM (DEXTROMETHORPHAN)	dextromethorphan	17856-0276	EDETATE DISODIUM
Atlantic Biologicals Corps	DELSYM (DEXTROMETHORPHAN)	dextromethorphan	17856-0276	ETHYLCELLULOSES
Atlantic Biologicals Corps	DELSYM (DEXTROMETHORPHAN)	dextromethorphan	17856-0276	FD&C YELLOW NO. 6
Atlantic Biologicals Corps	DELSYM (DEXTROMETHORPHAN)	dextromethorphan	17856-0276	HIGH FRUCTOSE CORN SYRUP

Delsym Dextromethorphan Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Delsym is a long-acting oral suspension built around dextromethorphan polistirex, an ion-exchange resin complex that releases dextromethorphan over approximately 12 hours. Its commercial differentiation depends less on the active ingredient than on controlled release, taste masking, pediatric usability, suspension stability, dosing accuracy and brand trust. The strongest opportunities are sugar-free or lower-sugar liquids, improved sensory performance, preservative reduction, unit-dose formats and differentiated delivery systems that remain compliant with the FDA over-the-counter cough-cold framework.

What is Delsym and how does its formulation differ from generic dextromethorphan?

Delsym contains dextromethorphan polistirex rather than conventional dextromethorphan hydrobromide. The polistirex complex is a polymeric resin system designed to provide extended release in an oral suspension.

Attribute	Delsym long-acting suspension	Conventional dextromethorphan liquid
Active form	Dextromethorphan polistirex	Usually dextromethorphan hydrobromide
Release profile	Approximately 12 hours	Usually 4 to 6 hours
Typical strength	30 mg dextromethorphan per 5 mL equivalent	Often 10 or 15 mg per 5 mL
Dosage form	Oral suspension	Solution or suspension
Primary differentiation	Extended dosing interval and branded sensory profile	Lower-cost active ingredient and simpler formulation
Key technical risk	Resin release, settling, taste and dose uniformity	Taste, stability and preservative performance

Delsym’s formulation architecture is built around the resin complex, not merely the use of a thickener. The excipient system must keep the polymeric drug complex uniformly dispersed, control sedimentation, maintain acceptable viscosity and support consistent delivery from the measuring device.

The current Delsym 12 Hour Cough Relief label identifies dextromethorphan polistirex as the active ingredient and lists inactive ingredients including sweeteners, viscosity or suspension-control components, preservatives, buffers, salts, colorants, flavoring components and purified water. Product-specific ingredient lists can differ by flavor and package configuration. DailyMed should be used as the controlling source for any manufacturing or regulatory assessment.[1]

What excipients are used in Delsym?

Delsym’s commercial formulation uses excipients that perform several simultaneous functions: vehicle formation, taste masking, suspension stabilization, preservation, pH control and consumer acceptability.

Functional excipient map

Excipient function	Likely formulation requirement	Commercial relevance
Sweetening	Mask resin-associated bitterness and support pediatric acceptance	Determines sugar, calorie and dental-positioning claims
Suspending system	Maintain uniform dispersion of dextromethorphan polistirex	Directly affects dose uniformity and “shake well” performance
Viscosity control	Slow settling without making the product difficult to pour	Important for pediatric dosing and bottle emptying
Preservative	Control microbial growth in a multidose aqueous product	Creates opportunities for preservative-reduced formats
Buffering	Maintain pH stability and preservative effectiveness	Can affect resin release and chemical stability
Chelation	Reduce metal-catalyzed degradation or improve preservative performance	May improve shelf-life robustness
Flavor and color	Improve taste, aroma and product recognition	Supports line extensions and repeat purchase
Humectant or solvent	Assist flavor delivery and mouthfeel	Can alter viscosity and sensory perception
Purified water	Continuous aqueous phase	Determines microbial and physical stability requirements

Public labels for Delsym products have identified ingredients such as ethylcellulose, methylparaben, propylene glycol, sodium citrate, sodium chloride, edetate disodium, sucrose, high-fructose corn syrup, colorants and purified water, although the precise composition depends on the product and flavor.[1]

The most important technical constraint is excipient interaction with dextromethorphan polistirex. A formulation change that improves suspension stability can also change release kinetics, mouthfeel or the amount of drug delivered from the resin complex. This creates a higher development burden than a conventional immediate-release dextromethorphan syrup.

What excipient strategies could improve Delsym?

The best strategies target measurable consumer and manufacturing problems rather than adding excipients without a clear performance objective.

1. Sugar-free or reduced-sugar suspension

A sugar-free Delsym variant could address diabetes, calorie sensitivity, dental concerns and retailer demand for lower-sugar pediatric products. The formulation would require replacement of sucrose and high-fructose corn syrup with a combination of high-intensity sweeteners, bulk sweeteners and texture modifiers.

Potential excipient systems include:

• Sucralose or acesulfame potassium for high-intensity sweetness.
• Sorbitol, glycerin or maltitol for body and mouthfeel.
• Polyols or soluble fibers to replace syrup solids.
• Natural flavor systems designed to suppress bitterness and resin-associated aftertaste.
• Alternative suspension polymers compatible with the polistirex release profile.

The primary risks are cooling effects from polyols, laxation at high exposure, altered viscosity, aftertaste and increased microbial or chemical stability complexity. A sugar-free claim would have greater commercial value if paired with a clearly improved sensory profile rather than a simple sweetener substitution.

2. Improved suspension and dose uniformity

Delsym requires shaking before use. Consumers may underdose or overdose if the resin complex settles rapidly or forms a hard sediment. A next-generation suspension could use a structured vehicle that produces:

• Slower sedimentation.
• Easy redispersion after storage.
• Lower viscosity during pouring.
• Less residue on the bottle and dosing cup.
• Consistent delivery after partial bottle use.

Possible technologies include xanthan gum, microcrystalline cellulose and carboxymethylcellulose systems, starch-based rheology modifiers, or polymer combinations engineered for thixotropy. Any change would require comparative release testing because the vehicle can influence diffusion from or exchange with the resin.

3. Preservative-reduced or preservative-free packaging

Multidose aqueous products normally require microbial control. A preservative-reduced Delsym format could use:

• Single-dose sachets.
• Unit-dose stick packs.
• Blow-fill-seal containers.
• Metered-dose oral dispensers.
• Smaller bottles with reduced in-use exposure.
• Packaging with improved closure and contamination resistance.

The commercial opportunity is strongest in pediatric and travel channels, where portability and clean-label positioning matter. The principal tradeoff is higher packaging cost and more complex filling operations.

4. Taste masking and sensory redesign

Dextromethorphan is bitter, and the resin complex can introduce an undesirable mouthfeel. A sensory redesign could use:

• Dual-layer flavor systems.
• Sweetener combinations that suppress bitterness rather than simply increasing sweetness.
• Encapsulated flavor particles.
• Mucoadhesive taste-masking polymers.
• pH optimization.
• Cooling or fruit flavor systems selected for pediatric acceptance.

Taste masking must not interfere with release testing, suspension stability or the drug’s interaction with the resin. Flavor changes can support line extensions without changing the active complex, but the regulatory burden depends on the scale of the formulation change.

What formulations are protected by Delsym-related intellectual property?

The commercially important IP is likely to be concentrated in the extended-release resin complex, manufacturing process, particle characteristics, release profile, suspension vehicle and brand assets. The active ingredient itself is old and cannot provide meaningful composition-of-matter exclusivity.

Patent categories relevant to Delsym

IP category	Potential protection	Competitive value
Resin-drug complex	Polymer, ion-exchange chemistry and loading process	High if claims remain enforceable
Release profile	Twelve-hour release, dissolution limits and pharmacokinetic performance	High for direct extended-release substitutes
Particle engineering	Resin particle size, coating or dispersion	Medium to high
Suspension vehicle	Rheology, redispersion and dose uniformity	Medium
Taste masking	Flavor, coating or polymeric barrier	Medium
Manufacturing process	Complexation, washing, drying and blending	High if difficult to design around
Packaging	Unit-dose or contamination-control systems	Low to medium
Trademarks	Delsym brand and product names	Commercially important but separate from formulation exclusivity

A patent search should separate legacy patents on dextromethorphan-resin technology from later patents covering specific Delsym formulations. Patent family members, continuations and terminal disclaimers can materially change the effective scope. Publicly available product labeling alone does not establish whether a formulation patent remains enforceable.

What is the FDA regulatory status of Delsym?

Delsym is an OTC cough suppressant product containing dextromethorphan. Dextromethorphan is addressed within the FDA’s OTC cough-cold regulatory framework, including the antitussive provisions historically codified at 21 C.F.R. Part 341 and subsequent OTC monograph orders.[2][3]

The regulatory pathway depends on the proposed change:

Proposed change	Likely regulatory issue
Flavor-only change	Labeling, stability and manufacturing documentation
New sweetener system	Safety, stability, microbial control and labeling
Sugar-free product	Excipient qualification and claim substantiation
New polymer vehicle	Drug release, dose uniformity and stability
New resin complex	Potentially a new drug evaluation issue
New 12-hour delivery system	Requires strong release and performance support
New device or metered dispenser	Device-drug combination and dose-delivery validation
New pediatric age claim	Safety, dosing and labeling review

A formulation that remains within the applicable OTC monograph framework can have a simpler route than a novel active or novel therapeutic indication. The monograph does not eliminate the need to demonstrate manufacturing control, stability, microbial quality, dose uniformity and appropriate labeling.

What is the Orange Book status of Delsym?

Delsym’s commercial protection should not be analyzed as if it were a conventional prescription product with a standard Orange Book patent-and-exclusivity profile. OTC monograph products generally do not rely on Orange Book listing in the same way as approved prescription NDAs.

The relevant competitive barriers are more likely to include:

1. Formulation and process patents.
2. Trade secrets covering resin complexation and release control.
3. Trademark protection for Delsym.
4. FDA monograph compliance.
5. Manufacturing scale and quality systems.
6. Consumer recognition of the 12-hour product.
7. Retail placement and pediatric recommendation patterns.

An Orange Book search should still be performed for any historical NDA or approved product record associated with a Delsym formulation. A lack of an applicable Orange Book listing would not mean that no patent or regulatory risk exists. It would mean that the competitive pathway is less dependent on the Hatch-Waxman listing framework.

When does Delsym lose exclusivity?

Delsym does not have a single publicly determinable “loss of exclusivity” date comparable to a patented prescription drug. The active ingredient has long been generic, while the product’s commercial position rests on the extended-release formulation, brand and manufacturing platform.

Exclusivity type	Delsym relevance
Active-ingredient patent	No meaningful current protection expected for dextromethorphan itself
OTC monograph status	Defines lawful active ingredient, dosage and labeling conditions
Formulation patent	May protect specific resin or suspension technology if unexpired
Trade secret	May protect process parameters without a public expiration date
Trademark	Can continue indefinitely with use and renewal
Market exclusivity	Not typically the primary barrier for an OTC monograph product

Generic competition can enter through immediate-release dextromethorphan liquids, capsules, lozenges and extended-release products. A competitor seeking to replicate Delsym’s 12-hour performance faces a higher technical burden than a company launching a conventional dextromethorphan product.

Which companies are challenging Delsym commercially?

The main competitive groups are:

• Private-label pharmacy and retail brands selling dextromethorphan hydrobromide.
• Branded OTC companies such as Haleon, Kenvue, Perrigo and other cough-cold manufacturers.
• Generic manufacturers offering dextromethorphan liquids, softgels, tablets and lozenges.
• Contract manufacturers supplying retailer-owned cough products.
• Consumer-health companies developing pediatric, sugar-free or natural-positioned cough products.

The direct threat is not limited to an identical polistirex suspension. Immediate-release alternatives can compete through lower price, broader distribution, private-label placement and different dosage forms. Delsym’s strongest defense is the combination of twelve-hour dosing, recognizable branding and an established liquid format.

What generic entry risks exist for Delsym?

Immediate-release substitution

Immediate-release dextromethorphan products are the lowest-barrier competitors. They can be priced substantially below Delsym and are widely available in multiple dosage forms. Their weakness is more frequent dosing.

Extended-release formulation entry

A direct extended-release competitor must address:

• Equivalent release duration.
• Dextromethorphan dose delivery.
• Resin or alternative controlled-release technology.
• Suspension uniformity.
• Taste and mouthfeel.
• Pediatric dosing.
• Stability over the labeled shelf life.
• Design-around risk for formulation and process patents.

Pediatric and household purchasing risk

Parents may shift to products with dosing syringes, lower sugar, fewer preservatives, smaller bottles or clearer dosing instructions. Excipient and packaging improvements therefore have defensive value even when they do not create strong patent barriers.

How strong is the Delsym patent estate?

The patent estate should be rated as potentially strong at the formulation-process level but limited at the active-ingredient level.

Estate component	Relative strength
Dextromethorphan molecule	Weak or expired
Twelve-hour resin delivery	Potentially strong, depending on live claims
Suspension excipients	Moderate and often design-around capable
Manufacturing process	Potentially strong if process know-how is difficult to replicate
Brand and trade dress	Strong commercial protection, not pharmaceutical exclusivity
OTC regulatory positioning	Moderate barrier, but not a patent right

Patent strength depends on claim construction, prosecution history, written-description support, continuity, expiration, maintenance fees and available design-around routes. A reliable opinion would require a current patent-family and litigation search. Public labeling does not establish claim scope.

What licensing deals and litigation affect Delsym?

No widely reported current licensing transaction or major public Paragraph IV campaign can be treated as the central Delsym competitive event based solely on the product label and OTC monograph materials. Paragraph IV litigation is primarily associated with abbreviated new drug applications for listed prescription products. It is not the default mechanism for competing with an OTC monograph cough suppressant.

Potential transactions would more likely involve:

• Acquisition of resin-release technology.
• Licensing of taste-masking systems.
• Contract manufacturing arrangements.
• Retailer private-label supply.
• Pediatric delivery devices.
• Flavor and sensory platforms.

Litigation risk may arise from formulation patents, trade dress, trademark claims, manufacturing know-how or product-liability allegations. Any current litigation assessment requires docket-level verification rather than inference from the product’s market position.

What commercial opportunities exist for Delsym excipients?

Highest-value opportunities

Opportunity	Consumer benefit	IP potential	Commercial assessment
Sugar-free 12-hour suspension	Lower sugar and calorie burden	Moderate	Strong line-extension opportunity
Unit-dose pediatric format	Portability and dosing control	Moderate	Attractive for travel and caregiver use
Improved redispersion	More reliable dose delivery	High if technically novel	Strong formulation opportunity
Preservative-reduced product	Clean-label positioning	Moderate	Packaging-dependent
Better taste masking	Higher pediatric acceptance	Moderate	Direct repeat-purchase effect
Metered oral dispenser	Reduced dosing error	Moderate	Device and packaging complexity
Smaller high-concentration dose	Less liquid per administration	High if release remains equivalent	Requires careful pediatric safety review
Sustainable bottle system	Lower packaging impact	Low to moderate	Retail and corporate-procurement value

The most defensible opportunity is a formulation platform that combines sugar reduction, rapid redispersion, improved taste and precise dosing without disrupting the established twelve-hour release profile. A single-excipient substitution is easier to copy and may offer limited commercial protection.

How does Delsym compare with competing dextromethorphan products?

Product strategy	Main advantage	Main weakness
Delsym polistirex suspension	Twelve-hour dosing and brand recognition	Higher price and suspension complexity
Generic immediate-release liquid	Low price and broad availability	More frequent dosing
Dextromethorphan softgel or tablet	Portability and no settling	Less suitable for young children
Lozenges	Local oral convenience	Limited pediatric applicability and different use experience
Combination cold product	Multiple symptom claims	Greater contraindication and interaction burden
Sugar-free liquid	Dietary positioning	Sweetener aftertaste and stability challenges

Delsym is best positioned where caregivers value reduced dosing frequency and a liquid dosage form. It is less protected in adult segments that prefer tablets, capsules or low-cost generic liquids.

Key Takeaways

• Delsym’s differentiation comes from dextromethorphan polistirex and its approximately twelve-hour release profile.
• The critical excipient functions are suspension control, taste masking, sweetness, preservation, buffering and dose uniformity.
• Sugar-free, preservative-reduced, unit-dose and metered-delivery formats offer the clearest commercial opportunities.
• The active ingredient provides little current exclusivity; formulation patents, manufacturing know-how and trademarks carry greater strategic value.
• Delsym should not be assessed solely through the conventional Orange Book or Paragraph IV framework because OTC monograph status is central to its market structure.
• A direct extended-release competitor faces greater technical challenges than a conventional immediate-release dextromethorphan generic.
• The strongest new-product concept is a low-sugar or sugar-free suspension with rapid redispersion, improved taste and more precise dosing.

FAQs

Can a company copy Delsym by using dextromethorphan hydrobromide?

It can market an immediate-release dextromethorphan product if the product complies with applicable FDA requirements. Dextromethorphan hydrobromide does not automatically reproduce Delsym’s twelve-hour release, sensory profile or formulation performance.

Is dextromethorphan polistirex an excipient or an active ingredient?

Dextromethorphan polistirex is the active pharmaceutical ingredient form used in Delsym. The polistirex resin is part of the drug complex and controls release; it is not merely an inactive suspension aid.

Does a sugar-free Delsym require a new drug application?

Not necessarily. The pathway depends on the formulation, labeling, active ingredient form, dosage claims and applicable OTC monograph conditions. A material change to release performance or the active complex could create a more substantial FDA review requirement.

Which excipient has the greatest effect on Delsym performance?

The suspension and rheology system can have the greatest practical effect because it influences settling, redispersion, pourability and dose uniformity. Its interaction with the polistirex complex must be evaluated alongside drug release.

Can a competitor patent a new Delsym flavor?

A flavor alone usually provides limited patent value unless it is part of a novel composition or performance-based formulation. Trademark, trade dress and consumer branding may provide stronger protection for a flavor-specific product.

References

1. DailyMed. (n.d.). Delsym 12 hour cough relief: Dextromethorphan polistirex oral suspension label. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). OTC monograph M012: Cough-cold, oral. https://www.accessdata.fda.gov/

3. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

4. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph drug products. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines/otc-monograph-reform

5. U.S. Patent and Trademark Office. (n.d.). Patent public search. https://ppubs.uspto.gov/pubwebapp/